| Domain | Key finding/statistic | Evidence type | Ontology suggestions | Source / date / DOI |
|---|---|---|---|---|
| Definition / disease scope | **Cervical dystonia (CD)** is an adult-onset focal dystonia affecting the neck, characterized by sustained or intermittent muscle contractions causing abnormal head/neck postures and movements; sensory trick (geste antagoniste) is a supportive sign. **General dystonia finding:** dystonia is defined as abnormal repetitive movements/postures caused by sustained or intermittent muscle contractions; touching the chin can reduce symptoms in CD (pqac-00000006). | Expert review; clinical classification | MONDO: cervical dystonia if available; MeSH: Dystonic Disorders; HPO: HP:0001332 Dystonia, HP:0031987 Abnormal head posture, HP:0000496 Abnormality of movement; UBERON: neck region | Thomsen et al., *Annu Rev Pathol* 2024;19:99-131. Published online 2023-09-22. DOI: 10.1146/annurev-pathmechdis-051122-110756 (pqac-00000006) |
| Key identifiers / classification | **General dystonia finding:** consensus classification uses axis I (age at onset, body distribution, temporal pattern, associated features) and axis II (etiology). Focal dystonia = one body region affected; late adulthood onset >40 years (pqac-00000005). | Expert consensus review | HPO: HP:0003577 Adult onset, HP:0001332 Dystonia; NCIT: focal dystonia | Thomsen et al., *Annu Rev Pathol* 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756 (pqac-00000005) |
| Epidemiology | **General isolated dystonia finding:** prevalence estimated at **52.7/100,000** or **30.9/100,000**; true prevalence may be higher because many cases remain un-/misdiagnosed; higher prevalence in females for most subforms (pqac-00000005, pqac-00000006). | Epidemiology summarized in review | NCIT: Prevalence; HPO: not applicable | Thomsen et al., *Annu Rev Pathol* 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756 (pqac-00000005, pqac-00000006) |
| Epidemiology / sex distribution | In a **1,701-patient** Italian idiopathic adult-onset dystonia registry, **cervical dystonia was present in 848/1701** at last exam; female:male ratio for CD **1.9 (95% CI 1.8-2.1)**. At onset, CD accounted for **681/1574 focal onsets**, female:male ratio **1.9 (1.7-2.0)** (pqac-00000007, pqac-00000008). | Large human registry | HPO: HP:0001332 Dystonia; NCIT: Female, Male | Velucci et al., *J Neurol Neurosurg Psychiatry* 2024;95:784-790. March 2024. DOI: 10.1136/jnnp-2023-332927 (pqac-00000007, pqac-00000008) |
| Phenotype / onset | CD usually begins between **45-50 years**; symptoms include dystonic neck posture plus, in some patients, dystonic tremor and pain; risk of spread to other body parts is described as **very low** in one focal-dystonia review/cohort summary (pqac-00000009). | Review with focal-dystonia cohort context | HPO: HP:0002418 Torticollis, HP:0001336 Tremor, HP:0012531 Neck pain, HP:0002829 Arthralgia/pain if needed | Salamon et al., *Int J Mol Sci* 2023;24:10745. 2023-06-28. DOI: 10.3390/ijms241310745 (pqac-00000009) |
| Phenotype / associated features | In the 1,701-patient registry, **sensory trick** occurred in **483/1701 (28.4%)**, tremor in **516/1701 (30.3%)**; among CD cases, **neck pain** occurred in **488/848 (57.5%)** with similar frequency by sex (58.1% women vs 56.6% men) (pqac-00000008). | Large human registry | HPO: HP:0003394 Sensory trick (suggested), HP:0001336 Tremor, HP:0012531 Neck pain | Velucci et al., *J Neurol Neurosurg Psychiatry* 2024. DOI: 10.1136/jnnp-2023-332927 (pqac-00000008) |
| Non-motor / quality of life | **General dystonia with CD-relevant data:** pain prevalence in CD ranges **67%-75%** in older systematic review data; a study of **116** patients with spasmodic torticollis found **71% lifetime social phobia**, correlated with body image/maladaptive attitude rather than objective severity (pqac-00000015). | Systematic review of non-motor manifestations | HPO: HP:0012531 Neck pain, HP:0000739 Anxiety, HP:0000729 Depression, HP:0000705 Social phobia (suggested) | Kuyper et al., *Movement Disorders* 2011;26:1206-1217. June 2011. DOI: 10.1002/mds.23709 (pqac-00000015) |
| Etiology | Most adult-onset isolated/CD cases are **idiopathic/sporadic and likely multifactorial**; monogenic causes are uncommon in isolated focal dystonia, and gene-environment interaction is suspected in sporadic cases (pqac-00000004, pqac-00000010). | Review; focal-dystonia sequencing study | MONDO: idiopathic isolated dystonia; HPO: HP:0001332 Dystonia | Brüggemann, *J Neural Transm* 2021;128:499-508. DOI: 10.1007/s00702-021-02299-y; Salamon et al., *Int J Mol Sci* 2023. DOI: 10.3390/ijms241310745 (pqac-00000004, pqac-00000010) |
| Genetic factors | In focal dystonia, genes most often implicated in CD screening studies include **THAP1, CIZ1, GNAL, ANO3**; in a Hungarian cohort of **121** focal dystonia patients (**74 CD**), 30-gene NGS found **209 heterozygous variants in 24 genes**, with **9 clinically/genetically relevant variants** total and overall diagnostic yield **7.4%** (pqac-00000009, pqac-00000010). | Human sequencing cohort | HGNC genes: THAP1, CIZ1, GNAL, ANO3, KMT2B, VPS16, KCNN2; NCIT: Next-Generation Sequencing | Salamon et al., *Int J Mol Sci* 2023;24:10745. 2023-06-28. DOI: 10.3390/ijms241310745 (pqac-00000009, pqac-00000010) |
| Pathogenic / candidate variants | CD-relevant variants in the Hungarian cohort included **ANO3 c.2276-6T>C** (splice region), **CIZ1 c.1820A>G p.Glu607Gly**, **KCNN2 c.1625G>A p.Arg542Gln**, **KMT2B c.3136C>T p.Arg1046Cys**, and **VPS16 c.1370T>C p.Leu457Pro**; most relevant variants occurred in earlier-onset cases (mean onset **31.6 years**) (pqac-00000010). | Human sequencing cohort | HGVS variant notation; HPO: HP:0003577 Adult onset, HP:0003621 Juvenile onset if early; NCIT: Variant of Uncertain Significance, Likely Pathogenic Variant | Salamon et al., *Int J Mol Sci* 2023. DOI: 10.3390/ijms241310745 (pqac-00000010) |
| Diagnostic genetics strategy | For focal dystonia/CD, detailed genetic work-up is most justified when there is **early onset, family history, or additional neurological/non-neurological features**; the 2023 cohort recommended targeted gene panels when budget is limited, with WES not clearly superior for yield in their sample (pqac-00000010). | Human cohort interpretation / expert recommendation | NCIT: Gene Panel Testing, Whole Exome Sequencing | Salamon et al., *Int J Mol Sci* 2023. DOI: 10.3390/ijms241310745 (pqac-00000010) |
| Mechanisms / systems neuroscience | **General dystonia finding with relevance to CD:** dystonia is a **network disorder** involving **basal ganglia, cerebellum, thalamus, and cortex** rather than only basal ganglia; impaired sensorimotor integration, reduced inhibition, and maladaptive plasticity are core mechanisms (pqac-00000006, pqac-00000004, pqac-00000000). | Expert review; mechanistic review | GO: synaptic signaling, regulation of neurotransmitter levels, motor control; UBERON: basal ganglion, cerebellum, thalamus, cerebral cortex; CL: Purkinje cell, striatal medium spiny neuron, cholinergic interneuron | Thomsen et al., *Annu Rev Pathol* 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756; Brüggemann, *J Neural Transm* 2021. DOI: 10.1007/s00702-021-02299-y; Rauschenberger & Ip, *Dystonia* 2024. DOI: 10.3389/dyst.2024.11793 (pqac-00000006, pqac-00000004, pqac-00000000) |
| Mechanisms / molecular pathways | **General dystonia finding:** implicated pathways include **gene transcription during neurodevelopment** (e.g., **KMT2B, THAP1**), **calcium homeostasis** (**ANO3, HPCA**), **striatal dopamine signaling** (**GNAL**), **ER stress response** (**EIF2AK2, PRKRA, TOR1A**), and **autophagy/lysosomal trafficking** (**VPS16**) (pqac-00000006). | Expert molecular review | GO: regulation of transcription, calcium ion homeostasis, dopamine receptor signaling pathway, response to endoplasmic reticulum stress, autophagy; CL: striatal neuron | Thomsen et al., *Annu Rev Pathol* 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756 (pqac-00000006) |
| Mechanisms / synaptic physiology | **General dystonia finding:** rodent models support abnormal neurotransmitter signaling, receptor trafficking, and synaptic plasticity in basal ganglia and cerebellum as common hallmarks. In DYT-TOR1A models, altered dopamine-acetylcholine balance disrupts corticostriatal LTD/depotentiation; D2 receptor activation paradoxically excites cholinergic interneurons (pqac-00000003, pqac-00000002). | Rodent/mechanistic review | GO: synaptic plasticity, long-term synaptic depression, dopaminergic signaling, cholinergic signaling; CL: cholinergic interneuron, Purkinje cell, deep cerebellar nucleus neuron | El Atiallah et al., *Curr Neuropharmacol* 2023;21:2310-2322. DOI: 10.2174/1570159X21666230718100156 (pqac-00000003, pqac-00000002) |
| Anatomy affected | Primary clinically affected structure is the **cervical musculature/neck region**; biologically implicated CNS nodes include **cortex, basal ganglia, thalamus, cerebellum**, and brainstem. CD may occur at rest, unlike some task-specific dystonias (pqac-00000004). | Review | UBERON: neck, skeletal muscle of neck, cerebellum, thalamus, basal ganglion, cerebral cortex; CL: Purkinje cell, medium spiny neuron | Brüggemann, *J Neural Transm* 2021. DOI: 10.1007/s00702-021-02299-y (pqac-00000004) |
| Diagnosis / clinical work-up | CD is primarily a **clinical diagnosis** by expert examination; work-up for idiopathic adult-onset dystonia in the Italian registry included **brain MRI or CT** to exclude structural causes and testing for **Wilson disease** and common monogenic dystonia variants (**TOR1A, THAP1, ANO3, GNAL**) as appropriate (pqac-00000007). | Large registry / clinical practice description | NCIT: Magnetic Resonance Imaging, Computed Tomography, Genetic Testing; HPO: HP:0001332 Dystonia | Velucci et al., *J Neurol Neurosurg Psychiatry* 2024. DOI: 10.1136/jnnp-2023-332927 (pqac-00000007) |
| Differential diagnosis | Important exclusions include **structural/acquired dystonia**, **Wilson disease**, and **monogenic non-degenerative dystonias**; expert reviews also note combined and complex dystonias, and autoimmune causes should be considered in subacute focal/segmental craniocervical presentations. | Registry protocol; expert review | MONDO: Wilson disease; NCIT: Differential Diagnosis | Velucci et al., *J Neurol Neurosurg Psychiatry* 2024. DOI: 10.1136/jnnp-2023-332927; Thomsen et al., *Annu Rev Pathol* 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756 (pqac-00000007, pqac-00000006) |
| Treatment / first-line | **Botulinum neurotoxin (BoNT) is standard symptomatic treatment** for CD; in the focal-dystonia cohort summary, BoNT therapy (types A and B) was described as essential for proper treatment, with muscle selection aided by **ultrasound and/or EMG** and the collum-caput concept (pqac-00000009). | Clinical review / implementation description | NCIT: Botulinum Toxin Type A, Botulinum Toxin Type B, Electromyography, Ultrasonography | Salamon et al., *Int J Mol Sci* 2023. DOI: 10.3390/ijms241310745 (pqac-00000009) |
| Treatment / BoNT landscape | **General therapeutic context with CD-specific pipeline data:** BoNTs are routinely used for CD. A 2024 toxin review lists formulations/trials including **PrabotulinumtoxinA (ABP-450, phase 2, migraine/cervical dystonia)**, **NeubotulinumtoxinA (phase 3, cervical dystonia)**, and **A2NTX (phase 1, cervical dystonia)** (pqac-00000014). | Therapeutics review / clinical pipeline summary | NCIT: Botulinum Toxin, Clinical Trial | Rasetti-Escargueil & Palea, *Toxins* 2024;16:261. June 2024. DOI: 10.3390/toxins16060261 (pqac-00000014) |
| Treatment / surgery | For refractory craniocervical dystonia including CD, **GPi deep brain stimulation** shows sustained benefit but variable durability. In a 2024 retrospective series of **24** patients, mean BFMDRS motor improved **55.3% at 6 months** and **56.6% at last follow-up**; **25%** had poor results (<30% improvement) (pqac-00000012, pqac-00000011). | Human surgical cohort | NCIT: Deep Brain Stimulation, Globus Pallidus Internus | Zhao et al., *Neurosurg Focus* 2024;56(6):E16. June 2024. DOI: 10.3171/2024.3.FOCUS23890 (pqac-00000012, pqac-00000011) |
| Prognosis / natural history | CD is usually **chronic**. In idiopathic adult-onset forms, spread and phenotype vary by body region; in craniocervical dystonia, symptoms often begin with blepharospasm or CD and may spread over time. Long-term DBS benefit can fluctuate, with nonresponse or secondary worsening in a subset (pqac-00000012, pqac-00000011, pqac-00000009). | Human cohort; review | HPO: HP:0003676 Progressive course; NCIT: Disease Progression | Zhao et al., *Neurosurg Focus* 2024. DOI: 10.3171/2024.3.FOCUS23890; Salamon et al., *Int J Mol Sci* 2023. DOI: 10.3390/ijms241310745 (pqac-00000012, pqac-00000011, pqac-00000009) |
| Prevention | No established **primary prevention** exists for idiopathic CD. Practical prevention is mainly **tertiary**: early recognition, optimized BoNT injection strategy, rehabilitation, and consideration of DBS in refractory disease to reduce disability and pain. | Inference from current care evidence | NCIT: Rehabilitation, Supportive Care, Deep Brain Stimulation | Supported by treatment reviews/cohorts (pqac-00000009, pqac-00000012, pqac-00000014) |
| Models / animal and cellular | **General dystonia model evidence:** rodent and primate models implicate both basal ganglia and cerebellum. Lesion, pharmacologic, optogenetic, chemogenetic, and genetic models show that cerebellar stimulation/inactivation can induce or suppress dystonia-like movements; abnormal Purkinje-cell and deep cerebellar nucleus firing are recurrent findings (pqac-00000000, pqac-00000001, pqac-00000002). | Rodent/primate experimental evidence | CL: Purkinje cell, deep cerebellar nucleus neuron, striatal projection neuron; GO: action potential, synaptic signaling | Rauschenberger & Ip, *Dystonia* 2024. DOI: 10.3389/dyst.2024.11793; Wilson & Hess, *Mov Disord* 2013. DOI: 10.1002/mds.25526; El Atiallah et al., *Curr Neuropharmacol* 2023. DOI: 10.2174/1570159X21666230718100156 (pqac-00000000, pqac-00000001, pqac-00000002) |


*Table: This table condenses key cervical dystonia knowledge-base facts across clinical, genetic, mechanistic, diagnostic, therapeutic, prognostic, and model domains. It distinguishes cervical-dystonia-specific evidence from broader dystonia findings and attaches ontology suggestions plus source metadata for downstream curation.*